Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The measles, mumps, and rubella (MMR) vaccine is a live-attenuated combination vaccine used to induce active immunity against measles (rubeola), mumps, and rubella (German measles). It typically contains attenuated strains of the three viruses, which stimulate the immune system to produce neutralizing antibodies. This specific entry refers to the MMR vaccine used in a clinical study led by Chiang Mai University to evaluate seroprevalence and vaccine response in HIV-infected adults in Northern Thailand. The vaccine is administered via injection and is a standard preventative measure for these three viral diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on measles + mumps + rubella vaccine.